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OBJECTIVE — Because endothelial cell dysfunction and inﬂammation are key contributors
to the development of complications in type 1 diabetes, we studied risk factors related to
endothelial dysfunction and inﬂammation (C-reactive protein and ﬁbrinogen, soluble vascular
cell adhesion molecule-1, intracellular adhesion molecule-1, and E-selectin, and ﬁbrinolytic
markers) in a subgroup of patients from the Diabetes Control and Complications Trial (DCCT)/
Epidemiology of Diabetes Intervention and Complications (EDIC) study cohort.
RESEARCHDESIGNANDMETHODS — Wedeterminedwhichoftheseriskfactorsor
clustersthereofareassociatedwiththepresenceofandsubsequentdevelopmentofnephropathy
and macrovascular complications (reﬂected by carotid intima-media thickness [IMT]).
RESULTS — After adjustment for conventional risk factors (age, sex, DCCT treatment group,
diabetes duration, A1C, systolic blood pressure, waist-to-hip ratio, total and HDL cholesterol,
and smoking status), ﬁbrinogen remained strongly associated with progression of internal and
common carotid IMT (P  0.01) and soluble E-selectin had a strong association with nephrop-
athy (P  0.01).
CONCLUSIONS — The best predictor for IMT progression in the DCCT/EDIC cohort was
plasma ﬁbrinogen, and the levels of soluble E-selectin discriminate patients with albuminuria
better than conventional risk factors.
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B
iomarkersarecirculatingmolecules,
proteins, or enzymes whose levels
provide independent diagnostic or
prognostic value for an underlying dis-
easestateorforcomplicationsthereof(1).
Studies over the last decade strongly sup-
port the idea that atherosclerosis and di-
abetic retinopathy and nephropathy
result from endothelial cell dysfunction
followedbylipidaccumulationandanin-
ﬂammatoryprocessaffectingbothmacro-
and microvasculature. Early studies fo-
cused on quantitative and qualitative
lipoprotein changes as biomarkers for the
development of diabetes complications
(2). However, although lipoproteins are
important biomarkers for vascular risk,
they do not completely account for the
excessofvascularcomplicationsindiabe-
tes.Therefore,morerecently,plasmabio-
markers of inﬂammation and endothelial
dysfunction have been investigated as
possible risk factors for diabetes complica-
tions.
Themajorityofthestudiesperformed
to examine these parameters have in-
cluded relatively small numbers of sub-
jects and had discrepant results. Some
studiesshowedelevationofinﬂammatory
markers such as interleukin-6 (IL-6) and
C-reactive protein (CRP) in patients with
nephropathyandothermicrovascularbut
not macrovascular complications (3).
However,increasedlevelsoftheseinﬂam-
matory markers have also been reported
intype1diabeticpatientswithoutclinical
evidence of complications (4).
The most extensive study of risk fac-
tors to date was conducted by Schram et
al. (5) in a subgroup of patients from the
European Diabetes (EURODIAB) Pro-
spective Complications Study. These au-
thors compared diabetic patients with
micro- and/or macrovascular complica-
tions with diabetic patients who were
complication free. They found increased
levels of CRP, IL-6, and tumor necrosis
factor in the patients with complications.
Theseauthorsalsodescribedacorrelation
between conventional vascular risk fac-
tors, including age, sex, diabetes dura-
tion, hypertension, lipid levels, and
smoking, with markers of inﬂammation
andendothelialdysfunction.Plasmalevels
of soluble vascular cell adhesion mole-
cule (sVCAM-1) and soluble E-selectin
(sE-selectin) were also strongly and inde-
pendently associated with inﬂammatory
markers, suggesting that endothelial dys-
function and inﬂammatory activity (re-
ﬂectedbypredominantlynonendothelium-
derived markers) are related in type 1
diabetes (5). The above study, however,
did not properly examine the association
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endothelial dysfunction markers as no ad-
justment for conventional risk factors was
performed, and micro- and macrovascular
complications were grouped.
The current literature does not pro-
vide a clear picture of the value of bio-
markers as predictors of diabetes
complications, although some articles
provide a basis for selecting biomarkers
morelikelytoprovideusefulinformation,
such as CRP (1,6–10) and ﬁbrinogen lev-
els (8,11–13), endothelial dysfunction
markers (sVCAM-1, soluble intracellular
adhesion molecule [sICAM-1], and sE-
selectin) (7,12,14,15), and the modula-
tors of ﬁbrinolysis, plasminogen activator
inhibitor 1 (PAI-1) (16), and tissue type-
speciﬁc plasminogen activator (tPA) (17).
Thus, we studied parameters of in-
ﬂammation and endothelial dysfunction
in the Diabetes Control and Complica-
tions Trial (DCCT)/Epidemiology of Dia-
betes Intervention and Complications
(EDIC) cohort, a large well-characterized
cohort of patients with type 1 diabetes, to
determine which parameter or cluster of
parameters are associated with the pres-
ence of nephropathy and macrovascular
complications. Because the number of
events related to macrovascular disease in
the cohort was rather small, carotid
intima-media thickness (IMT) was used
as a surrogate. Data obtained in the
DCCT/EDIC study have shown that ca-
rotid IMT is a sensitive marker for coro-
nary and cerebrovascular disease in
patients with type 1 diabetes (18). We
chose CRP and ﬁbrinogen as inﬂamma-
tory markers and sICAM-1, sVCAM-1,
sE-selectin, tPA, and PAI-1 as markers
of endothelial dysfunction.
RESEARCH DESIGN AND
METHODS— The DCCT enrolled
and followed 1,441 patients with type 1
diabetes between 1983 and 1993 to de-
termine whether intensive diabetes man-
agement would prevent complications
(19).ThestudywasstoppedinJune1993
because it was conclusively shown that
intensive management of type 1 diabetes
delayed development and progression of
retinopathy, neuropathy, and nephropa-
thy.TheDCCTwasfollowedbytheEDIC
study, which is a noninterventional epi-
demiologic investigation designed to
study the development of vascular dis-
eases in patients who were part of the
DCCT. EDIC has documented the devel-
opment and progression of macrovascu-
lar disease and nephropathy through
repeated measurements of carotid IMT
(macrovascular disease) and serum creat-
inine,estimatedglomerularﬁltrationrate,
and albumin excretion rate (AER) (ne-
phropathy)sinceitsinceptionin1994.In
1996 a Program Project Grant (PPG) was
obtained by the Medical University of
South Carolina to perform ancillary stud-
ies on the DCCT/EDIC cohort. A total of
1,063 EDIC participants agreed to partic-
ipateinthePPGstudy.Theﬁrstbloodand
urine collection for the PPG study, ob-
tained in 1997–1999, was used to mea-
sure the inﬂammation/endothelial cell
dysfunction parameters reported in this
article, and these measurements were
linked with clinical parameters from the
DCCT/EDIC cohort, including history of
clinicaleventsandriskbehaviors(suchas
smoking) and physical examination, as
wellasbloodpressure,routineelectrocar-
diograms, carotid IMT, lipid levels, A1C,
and AER. The study was approved by the
institutional review boards of all partici-
pating institutions, and each participant
gave written informed consent.
Quantitation of biomarkers
Serum levels of sICAM-1, sVCAM-1, and
sE-selectin were determined using
SearchLight Proteome Arrays (Pierce Bio-
technology, Rockford, IL) using Array-
Vision software for data analysis.
Interassay coefﬁcients of variation (CVs)
for sICAM-1, sVCAM-1, and sE-selectin
were, respectively, 10.7, 10.6, and 5%,
and intra-assay CVs were, respectively,
4.5, 4.3, and 2%. Plasma concentra-
tionsofﬁbrinogenweredeterminedusing
a commercially available assay using an
ST4 agglutinometer (Diagnostica Stago)
as described previously (11). Inter- and
intra-assay CVs were 6.4 and 3.9%, re-
spectively. Serum CRP was measured by
high-sensitivity immunonephelometry
withintra-andinterassayCVsof11and
2% as described (20). Quantitation of
tPA antigen and activity were determined
using commercially available enzymoim-
munoassays (TintElize tPA and Chromol-
ize tPA, respectively; Trinity Biotech, St.
Louis, MO). Interassay CVs for the two
assays averaged 6.6 and 5.3%, respec-
tively, whereas the intra-assay CVs aver-
aged 4.1 and 4.0%, respectively. PAI-1
antigen and activity levels were deter-
mined using commercially available en-
zymoimmunoassays (TintElize PAI-1 and
Chromolize PAI-1, respectively; Trinity
Biotech).TheinterassayCVsforthesetwo
assays averaged 8.8 and 10.8%, whereas
the intra-assay CVs averaged 4.7 and
3.5%. We performed masked determina-
tions in 69 to 86 duplicate samples from
EDIC patients and the coefﬁcients of reli-
ability (calculated by EDIC) were 0.938
for sVCAM-1, 0.918 for sVCAM-1, 0.946
forPAI-1,0.926forﬁbrinogen,and0.999
for CRP.
Statistical analysis
Outcome variables. According to the
EDIC protocol, renal assessment and
blood collection were performed in alter-
nate years. Thus, AER was calculated as
the average of measurements performed
on urine specimens collected within the
2-year period around the time of collec-
tion of blood samples used for biomarker
assays. Patients with AER 40 mg/24 h
were considered to have normal urine al-
buminlevels;thosewithAER40mg/24
h were classiﬁed as having abnormal
urine albumin levels.
Macrovascular disease was assessed
by internal and common carotid IMT as-
sessed by ultrasonography between 1994
and 1996, at approximately year 6 of
EDIC and 3 years before the collection of
thesamplesusedforthisreport(21).Cor-
responding year 1 IMT measurements for
internal carotid and common carotid
were used as covariables to assess pro-
gression of IMT. A description of IMT
measurements was detailed earlier
(21,22)
Modeling process. A multistage model-
ing process was used to test the primary
hypothesis that inﬂammation/endothelial
dysfunction markers predict diabetes
complications after adjustment for
knownriskfactors.Theﬁrststageofanal-
ysis was an univariate analysis in which
each outcome variable was associated
with each candidate marker. The candi-
date biomarkers were as follows:
sVCAM-1, sICAM-1, sE-selectin, PAI-1
activity and mass, tPA activity and mass,
CRP, and ﬁbrinogen. The natural loga-
rithms tPA mass, PAI-1 activity and mass,
sE-selectin, and sVCAM-1 were taken be-
cause of highly skewed levels. All regres-
sion models controlled for age, sex,
DCCT treatment group (intensive and
conventional randomization groups), di-
abetes duration, concurrent A1C, systolic
blood pressure, waist-to-hip ratio, total
and HDL cholesterol levels, and smoking
status after initial univariate associations
were examined in stage 1.
During the latter stages of the analy-
sis, biomarkers were grouped for analysis
according to their perceived biological
function. Three subgroups were identi-
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ers of ﬁbrinolysis, and 3) inﬂammatory
mediators (ﬁbrinogen and CRP). For ﬁ-
brinolysis, two different models were cre-
ated (one with mass measurements and
another with activity measurements).
Mass and activity measurements of PAI-1
were not included together in the same
model as they are highly correlated (r 
0.49) and thus would contribute to mul-
ticollinearity in the model. Similarly, the
mass and activity measures of tPA were
notincludedtogetherinthemodels.Each
subgroupofvariableswasenteredintore-
gression models separately. Collinearity
within a biological domain was assessed
bythevarianceinﬂationfactors;nosignif-
icant collinearity was detected. Partial F
testing (or likelihood ratio testing) was
used to determine whether addition of a
biomarker(s) signiﬁcantly enhanced
outcome prediction over conventional
variables.
All sets of multivariable regression
models that examined associations be-
tween investigational variables and ne-
phropathy, internal IMT, and common
carotid IMT after adjustment for conven-
tional risk factors were constructed, and
optimal models were chosen on the basis
of partial F testing and likelihood ratio
testing. Investigational variables were
added by category (e.g., inﬂammation,
ﬁbrinolysis variables [activity or mass],
and adhesion molecules).
To measure the strength of the asso-
ciations in the logistic regression models,
theNagelkerke’spseudo-R
2(23)andHar-
rell’s C statistic (24) were used. A value of
0.5representsachanceprediction,values
0.8 are considered discriminative, and
the discrimination of the model is im-
proved as the C value approaches 1.0.
All data management and analyses
were done using the SAS system (version
9.1.3; SAS Institute, Cary, NC). The type
I error rate was determined to be 0.05 a
priori, and no correction for multiple
comparisons was applied to the reported
P values.
RESULTS— At the time of blood sam-
ple collection, the mean  SD age of the
patients was 39  7 years and 55% were
male. Duration of diabetes was 17.5  4.8
monthsandA1Cwas8.21.3%.BMIwas
27.2  4.2 kg/m
2 and natural waist-to-hip
ratio was 0.8  0.1. Systolic and diastolic
bloodpressureswere12014and759
mmHg. Total, HDL, and LDL cholesterol
levels were, respectively, 189.0  35.3,
56.0 14.7, and 115.0 30.5 mg/dl. Tri-
glyceride levels were 89.0 63.3 mg/dl. In
some patients collection of blood for bio-
markers was not performed or was incom-
plete in 1997–1999, and, therefore, some
biomarkerswereassayedinareducednum-
ber of samples. Not all outcome variables
were obtained for a few patients. Conven-
tional risk factors for 1997–1999 in all pa-
tients enrolled in the PPG as well as
descriptive statistics of the outcomes and
markersexaminedinthisstudyaresumma-
rized in Table 1.
Logistic and linear regression analy-
ses between the investigational variables,
AER, and internal and common carotid
IMT without adjustment for any other
variables were performed (see supple-
mental Table A1 of the online appendix
available at http://dx.doi.org/10.2337/
dc08-0659.). A signiﬁcant positive asso-
ciationofPAI-1activitywithbothinternal
(P0.01)andcommoncarotidIMT(P
0.01) and a negative association of tPA
activity and internal carotid IMT (P 
0.01) were observed. tPA mass was asso-
ciated with nephropathy (P  0.03) as
well as with internal (P  0.01) and com-
mon (P  0.01) carotid IMT. Of the
adhesion molecules, sE-selectin was sig-
niﬁcantly associated with nephropathy
(P  0.01), and sICAM-1 was associated
with internal carotid IMT (P  0.03). No
signiﬁcant associations of ﬁbrinogen and
CRP levels with nephropathy were ob-
served (P  0.13 and P  0.77, respec-
tively). A strong association with internal
and common carotid IMT was observed
for ﬁbrinogen (P  0.01 for both IMT
measurements)butnotforCRP(P0.54
and P  0.84; respectively). Because CRP
was not associated by simple logistic and
linear regression analysis with either
Table 1—Descriptive statistics of demographic variables, covariates, and outcome variables
Sample
size Mean  SD
Interquartile
range
Conventional risk factors
Age (years) 1,063 39.2  7.0 10.0
DCCT experimental group (%) 1,063 51 —
Type 1 diabetes duration (years) 1,063 17.5  4.8 7.7
A1C (% of hemoglobin) 1,045 8.2  1.3 1.7
Male sex (%) 1,063 55 —
Smoker (%) 1,042 19 —
Systolic blood pressure (mmHg) 1,045 120.0  13.9 18.0
Diastolic blood pressure (mmHg) 1,045 75.0  9.3 12.0
Height (cm) 1,046 172.5  9.4 13.7
Weight (kg) 1,046 81.3  15.5 21.7
BMI (kg/m
2) 1,044 27.2  4.2 5.1
Natural waist-to-hip ratio 1,045 0.8  0.1 0.1
Total cholesterol (mg/dl) 1,027 189  35.3 44.0
HDL cholesterol (mg/dl) 1,027 56  14.7 19.0
LDL cholesterol (mg/dl) 1,021 115  30.5 39
Triglycerides (mg/dl) 1,027 89  63.3 51.0
Biomarkers
PAI-1 activity (IU/ml) 928 4.5  6.9 4.5
PAI-1 mass (ng/ml) 990 32.2  24.8 30.6
sE-Selectin (ng/ml) 752 58.7  35.7 38.4
sICAM-1 (ng/ml) 812 332.4  123.7 158.6
sVCAM-1 (ng/ml) 782 685.8  442.4 418.1
tPA activity (IU/ml) 988 1.0  0.5 0.5
tPA mass (ng/ml) 964 6.3  5.0 4.3
Fibrinogen (mg/dl) 911 309.5  106.9 128.0
CRP (mg/l) 951 3.1  4.6 3.0
Outcomes
AER (mg/24 h) 1,020 87  441.7 14.4
Micro-/macroalbuminuria (AER
40 mg/24 h) (%)
1,020 14 —
Internal IMT year 6 (units) 958 0.7  0.3 0.1
Common IMT at year 6 ( units) 970 0.6  0.1 0.2
Risk factors in DCCT/EDIC and complications
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nephropathy, CRP was not entered in
the multivariate linear or logistic mod-
els that examined associations between
the investigational variables and micro-
and macrovascular complications.
Table 2 summarizes the signiﬁcance
of the association of each group of vari-
ables studied with nephropathy and in-
ternal and common carotid IMT (year 6)
after adjustment for conventional cardio-
vascular disease (CVD) risk factors. Table
2 shows a statistically signiﬁcant associa-
tion (P  0.02) of nephropathy with the
set of adhesion molecules, after adjust-
ment for conventional CVD risk factors,
as well as a signiﬁcant association (P 
0.01) of ﬁbrinogen with progression of
internal and common carotid IMT (year
6), after adjustment for conventional
CVD risk factors. The association be-
tween outcomes and biomarkers was not
improved by combining biomarkers from
different domains.
Table 3 summarizes the multivariate
logistic and linear regression analyses ex-
aminingtherelationshipofallbiomarkers
studied and the vascular outcomes (ne-
phropathy assessed by AER and internal
and common carotid IMT progression).
As seen in Table 3, sE-selectin shows
strong evidence for an association with
nephropathy, even after correction for
conventional risk factors (total and HDL
cholesterol, smoking, age, sex, A1C,
blood pressure, and waist-to-hip ratio),
duration of diabetes, and DCCT random-
ization group (P  0.01). sE-selectin en-
hanced discrimination over that pro-
vided by conventional risk factors of pa-
tients with abnormal AER from patients
with normoalbuminuria (C statistic in-
creased from 0.80 to 0.84). Adding either
ﬁbrinolytic factors or acute inﬂammatory
markers such as ﬁbrinogen to sE-selectin
Table 2—Signiﬁcance of the association of endothelial cell dysfunction and inﬂammation markers with nephropathy and cardiovascular
disease in the presence of conventional risk factors
Biological domain
Nephropathy Internal carotid IMT (year 6) Common carotid IMT (year 6)
LRT d.f. P
Partial
F test d.f.* P
Partial
F test d.f.* P
Fibrinolysis (activity) 2.62 2 0.27 1.76 2, 756 0.17 4.43 2, 777 0.01
Fibrinolysis (mass) 0.17 2 0.92 0.47 2, 790 0.62 0.09 2, 817 0.91
Adhesion molecules 10.25 3 0.02 1.03 3, 605 0.38 0.07 3, 628 0.98
Inﬂammation 0.44 1 0.51 12.72 1, 762 0.01 7.90 1, 787 0.01
d.f., degree of freedom. *Numerator, denominator.
Table 3—Final models of multivariate logistic and linear regression analysis
Outcome, method, and
model* †S E ( ) STD† P
Sample size
Coefﬁcient of
determination Concordance index
M1 M2 M3 M1 M2 M3 M1 M2 M3
Nephropathy
Logistic 0.72 0.25 0.21 0.01 987 711 690 0.24 0.08 0.32 0.80 0.68 0.84
sE-Selectin (ng/ml)**
sVCAM-1 (ng/ml)** 0.26 0.26 -0.07 0.31
sICAM-1 (ng/ml)** 0.40 0.36 -0.08 0.26
Internal IMT (year 6)
Linear
Fibrinogen (mg/dl) 0.09 0.03 0.10 0.01 897 825 775 0.43 0.02 0.41 — — —
Common IMT (year 6)
Linear
PAI-1 Activity (IU/ml)** 0.01 0.00 0.06 0.05 927 823 791 0.37 0.02 0.37 — — —
tPA Activity (IU/ml)** 0.02 0.01 0.09 0.01
Linear
Fibrinogen 0.02 0.01 0.08 0.01 927 834 800 0.37 0.02 0.38 — — —
*Estimatesareadjustedforage(years),treatmentgroup(reference:standardtreatment),durationoftype1diabetes(years),A1C(percentage),sex(reference:male),
smokingstatus(reference:smoker),systolicbloodpressure(reference:millimetersofmercury),naturalwaist-to-hipratio,HDLcholesterol(milligramsperdeciliter),
and total cholesterol (milligrams per deciliter). IMT outcomes at year 6 are also adjusted for corresponding IMT readings at year 1. †The reported values are the
change in the log odds for a 1-unit change (unstandardized  values) ora1S Dchange (standardized  values) in the biological parameter (for logistic regression
models)orthechangeinIMTforeithera1-unitchange(unstandardized)or1SDchange(standardized)forlinearregressionmodels.Oddsratiosforthesamechange
can be obtained by exponentiating the estimated  values. For example,a1S Dchange in the natural logarithm of PAI-1 activity (International Units per milliliter)
increases the odds of nephropathy by 1.0602 (P  0.4013). ‡Only applicable to the logistic model. §Nagelkerke’s pseudo-R
2 is reported for the logistic model and
the adjusted R
2 for the linear regression models. Regression model 1: composed of conventional risk factors: age (years), treatment group (reference: standard
treatment), duration of diabetes (years), A1C (percentage), sex (reference: male), smoking status (reference: smoker), systolic blood pressure (reference: millimeters
of mercury), natural waist-to-hip ratio, HDL cholesterol (milligrams per deciliter), and total cholesterol (milligrams per deciliter). IMT outcomes at year 6 are also
adjusted for corresponding IMT readings at year 1. This model is denoted as M1 for sample size, coefﬁcient of determination, and concordance index. Regression
model 2: composed of only the speciﬁed biomarkers. This model is denoted as M2 for sample size, coefﬁcient of determination, and concordance index. Regression
model 3 (M3): models 1 and 2 combined. **Natural log transformed.
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ination of sE-selectin. Additive or syner-
gistic interactions with other adhesion
molecules were not observed (data not
shown). Thus, the ﬁnal predictive model
for nephropathy consisted of the main ef-
fects of the three adhesion molecules.
Multivariable linear regression inves-
tigatingtheassociationofbiomarkersand
internal and carotid IMT incorporated, as
correction factors, the conventional risk
factors mentioned for nephropathy and
the measurements performed for IMT at
year 1 of EDIC. This way progression be-
tween the measurements of years 1 and 6
could be assessed. Interestingly some of
the associations were strongly affected by
the correction by conventional risk fac-
tors.Onlyﬁbrinogenremainedassociated
with year 6 internal carotid IMT (P 
0.01), but ﬁbrinogen levels (P  0.01),
PAI-1 activities (P  0.05), and tPA activ-
ity (P  0.01) remained associated with
year 6 common carotid IMT. Adding dif-
ferent biomarkers did not strengthen the
association of the levels of single bio-
markers with internal carotid or common
carotid IMT progression.
CONCLUSIONS — The identiﬁca-
tion of inﬂammation and endothelial dys-
function markers associated with the
development of nephropathy and CVD in
patients with type 1 diabetes has consid-
erable clinical implications. This study
is the ﬁrst conducted on a large cohort
of type 1 diabetic patients (1,063 pa-
tients from the well-characterized
DCCT/EDIC cohort) that addresses the
association of these markers to the de-
velopment of complications.
Simple logistic and linear regression
analyses of our data suggested that the
levels of ﬁbrinogen, soluble cell adhesion
molecules, and PAI-1 and both tPA activ-
ity and tPA mass are the most promising
biomarkers to assess the risk for develop-
ment of complications in type 1 diabetic
patients. On the other hand, CRP levels
were not associated with either macro- or
microvascular complications in this co-
hort of type 1 diabetic patients. Based on
these results, we performed additional
statistical studies exploring the correla-
tion of ﬁbrinolytic factors (activity and
mass), ﬁbrinogen, and cell adhesion mol-
eculeswiththedevelopmentofcomplica-
tions after adjustment for conventional
risk factors.
After the adjustment for conventional
risk factors, the levels of sVCAM-1, sI-
CAM-1, and sE-selectin, as a group,
showed a statistically signiﬁcant associa-
tionwithnephropathy,inagreementwith
several published reports. Such associa-
tions had been reported previously in
other smaller cross-sectional studies, in
whichsICAM-1levelswerereportedtobe
signiﬁcantly increased in patients with
type 1 diabetes compared with nondia-
betic subjects and in diabetic patients
with complications compared with those
without (7,12) and in a larger study (n 
540), in which sVCAM-1 and sE-selectin
levels had positive associations with al-
buminuria and CVD (14). Costacou
etal.(15)alsofoundsE-selectintobean
independent predictor of coronary
heart disease in a case-control study of
patients with type 1 diabetes from the
Pittsburgh Epidemiology of Diabetes Com-
plications study, but we did not observe
such an association. In agreement with our
negative results, Leinonen et al. (25) re-
ported in patients with type 2 diabetes
that levels of soluble cell adhesion mole-
cules, although elevated, do not correlate
with internal carotid IMT or with clinical
CVD (25).
The EURODIAB Prospective Compli-
cations Study recently investigated two
determinants of inﬂammatory activity,
conventional risk factors for athero-
thrombosis and plasma concentrations
ofsVCAM-1andsE-selectin,asindexesof
endothelial dysfunction. The markers of
inﬂammatory activity (CRP, IL-6, and tu-
mor necrosis factor) were associated with
conventional risk factors including sex,
diabetes duration, level of glycemic con-
trol, BMI, HDL cholesterol (inversely),
triglycerides, and systolic blood pressure.
PlasmalevelsofsVCAM-1andsE-selectin
were also strongly and independently
associatedwiththeseinﬂammatorymark-
ers, suggesting that endothelial dysfunc-
tion and inﬂammatory activity are related
events in type 1 diabetes (5). However,
because inﬂammation is strongly linked
with conventional risk factors as well as
with biomarkers of endothelial cell dys-
function in type 1 diabetes when all fac-
tors are taken into consideration, the
valueofthebiomarkersofendothelialcell
dysfunction to predict cardiovascular
complications is not superior to that of
conventional risk factors.
Thevalueofinﬂammationmarkersas
predictors of macro- or microvascular
complications in diabetic patients is not
clear, particularly in the case of CRP,
which did not show any correlation with
micro- or macrovascular disease in our
study. These results are in keeping with
our cross-sectional study of DCCT-EDIC
participants, in which serum CRP levels
were correlated with BMI and glycemia
but were not associated with micro- or
macrovascular complications (20). Al-
though CRP has been heralded as the op-
timal biomarker for improving vascular
risk prediction (1), the data for type 1 di-
abetes are contradictory. Several groups
have reported elevated CRP levels in dia-
betic patients (6,7), whereas others failed
to reproduce this ﬁnding (8). Some stud-
ies have shown a correlation between
highCRPlevelswithincreasedIMTofthe
carotid artery (9). Other studies reported
thatCRPisindependentlyassociatedwith
development of diabetic nephropathy
(6,10). However, elevated CRP levels
have also been detected in patients with
type 1 diabetes without evidence of mac-
rovascular disease (7), and other studies
have failed to show a signiﬁcant correla-
tion between CRP levels and small vessel
vasculitis (13). Further, these studies
failed to demonstrate that CRP levels are
an independent marker for the develop-
ment of vascular complications or ne-
phropathyinpatientswithtype1diabetes
(8,12) in agreement with our results.
Fibrinogen levels have been shown to
beassociatedwithglomerularbasalmem-
brane thickening and to be increased in
patients with diabetic nephropathy after
correction of other markers of inﬂamma-
tion (8). However, it has also been re-
ported that the increase in ﬁbrinogen
levels observed in type 1 diabetic patients
with microvascular complications loses
signiﬁcance when the analysis is adjusted
for diabetes duration and glycemic con-
trol(12).Apreviousstudyperformedina
group of 909 patients from the DCCT/
EDIC cohort showed signiﬁcant correla-
tions between ﬁbrinogen levels and
urinaryAERinmen(r0.13,P0.003)
and a low average brachial index in
women (r  0.13, P  0.00) (11). In
the present study, ﬁbrinogen levels had a
strong predictive value for the develop-
ment of macrovascular disease, showing
thestrongestassociationwithprogression
of internal carotid IMT, whereas a weaker
association was seen with PAI-1 and tPA
activities. Other groups had reported that
patients with type 1 diabetes of 1 year
duration had higher levels of tPA than
those with duration of diabetes of 1
year,suggestingthatendothelialdysfunc-
tionisaveryearlyeventintype1diabetes
(17).PAI-1activityhasalsobeenreported
to be decreased in patients with type 1
diabetes (16). It is possible that these cor-
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given that the mean duration of diabetes
at admission to the original DCCT trial
was 5.6 years.
In summary, the measurement of
plasma ﬁbrinogen levels and of the levels
of soluble cell adhesion molecules are
strongly correlated with the presence or
development of vascular disease and dia-
betic nephropathy in the DCCT/EDIC
cohort of type 1 diabetic patients. How-
ever, our study, as with previously pub-
lishedstudies,haslimitationsbecauseitis
mostly cross-sectional with a very narrow
period of follow-up for IMT, and, there-
fore, the predictive value of our ﬁndings
needs to be conﬁrmed and validated.
Studies that we have now initiated will
investigate the predictive power of these
markers by measuring them in samples
collected at enrollment into the DCCT/
EDIC cohort and in this way clearly de-
ﬁning whether the measurements can
predictthedevelopmentofcomplications
10–20 years later.
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